50 results on '"Takeda, S"'
Search Results
2. P.313Improvement of human induced pluripotent stem cells (hiPSCs) - based therapy of Duchenne muscular dystrophy by using mesenchymal stem cells (MSCs)
3. P.340Viltolarsen, exon 53 skipping drug, in patients with Duchenne muscular dystrophy: additional analysis of Japanese phase I/II study
4. DMD CLINICAL THERAPIES I
5. DMD CLINICAL THERAPIES II
6. Comparative high resolution proteomic analysis of dystrophic mouse models reveals a core dystrophic proteome and the impact of aging
7. Data analysis of dystrophinopathy national registry in Japan
8. Age-related and mutation-independent proteomic changes in dystrophic mouse muscle
9. Current status of dystrophinopathy national registry in Japan
10. A comparative study of care and support for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosis
11. Ablation of MMP-9 promotes resolution of inflammation and regeneration by modulating chemotaxis in early stage but exacerbates fibrosis in late stage in mdx mice
12. Combined cell and gene therapy to treat merosin deficient congenital muscular dystrophy
13. Trends of steroid therapy for Duchenne muscular dystrophy in Japan
14. Exon 53 skipping of the dystrophin gene in patients with Duchenne muscular dystrophy by systemic administration of NS-065/NCNP-01: A phase 1, dose escalation, first-in-human study
15. P.241 - Comparative high resolution proteomic analysis of dystrophic mouse models reveals a core dystrophic proteome and the impact of aging
16. P.104 - Data analysis of dystrophinopathy national registry in Japan
17. D02 - Age-related and mutation-independent proteomic changes in dystrophic mouse muscle
18. Generation of clusters of dystrophin revertant fibers requires muscle regeneration and tests the function of dystrophin/utrophin transgenes
19. G.P.258
20. G.P.259
21. G.P.85
22. P.116 - A comparative study of care and support for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosis
23. P.102 - Current status of dystrophinopathy national registry in Japan
24. P.7.9 Current status of dystrophinopathy patient registry in Japan: Remudy
25. S.P.38 Infrastructure for new drug development to treat muscular dystrophy – Current status of patient registration in japan: REMUDY
26. P4.46 Expression of human GNE through adeno-associated virus mediated therapy delays progression of myopathy in the DMRV/hIBM mouse model
27. G.P.359 - Ablation of MMP-9 promotes resolution of inflammation and regeneration by modulating chemotaxis in early stage but exacerbates fibrosis in late stage in mdx mice
28. G.P.281 - Combined cell and gene therapy to treat merosin deficient congenital muscular dystrophy
29. G.P.251 - Exon 53 skipping of the dystrophin gene in patients with Duchenne muscular dystrophy by systemic administration of NS-065/NCNP-01: A phase 1, dose escalation, first-in-human study
30. G.P.43 - Trends of steroid therapy for Duchenne muscular dystrophy in Japan
31. P1.03 Disruption of dystroglycan–pikachurin interaction underlies the molecular pathogenesis of eye abnormalities in dystroglycanopathy
32. P3.04 Skipping of exons 6 and 8 of the DMD gene has been achieved in myogenic cells from an exon-7 deleted DMD patient: direct application of antisense sequences found in study with canine muscular dystrophy
33. P4.41 REMUDY – DMD/BMD patient registry in Japan
34. T.I.4 Potential of muscle stem cells and cell therapy for Duchenne muscular dystrophy
35. EM.O.2 Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy
36. M.I.5 The dystrophic dogs as an excellent animal model of Duchenne muscular dystrophy (DMD)
37. G.P.4.06 Dislocation of neuronal nitric oxide synthase contributes to muscle atrophy in amyotrophic lateral sclerosis
38. G.P.2.12 Generation of a model mouse for Fukuyama congenital muscular dystrophy carrying a retrotransposal insertion in the 3′ UTR in the fukutin gene: Therapeutic benefit of enhanced dystroglycan glycosylation to dystroglycanopathy
39. G.P.1.13 Deflazacort induced severe skeletal muscle wasting and inguinal herniation in normal Beagle dogs
40. C.P.3.12 POMGnT1-null myoblasts poorly proliferate in vitro
41. C.P.3.14 Basement membrane fragility underlies embryonic lethality in fukutin-null mice
42. T.O.2 Systemic delivery of morpholino oligonucleotides to skip mutations in the dystrophin gene of the mouse and dog
43. Laminin α2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice
44. G.P.259: Nationwide patient registry of GNE myopathy in Japan
45. G.P.258: National registry of Japanese dystrophinopathy patients: Remudy
46. G.P.85: Truncated dystrophin with exon 45–55 deletion induced muscle atrophy and fiber type change through the hyper-nitrosylation of the ryanodine receptor type-1 and constant release of Ca2+to the cytosol
47. Reduction of serum IgG level and peripheral T-cell counts are correlated with CTG repeat lengths in myotonic dystrophy patients
48. G.P.5 06 Dislocated neuronal nitric oxide synthase results in muscle atrophy during tail suspension
49. P.7.9 Current status of dystrophinopathy patient registry in Japan: Remudy.
50. P.P.4 04 Disruption of fukutin causes dysmyelination of peripheral nerve
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.